News


Atriva Therapeutics Receives EU Award for Biomarker Validation

Posted on

Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced that they have received the Biomarker Validation Award as part of the European Interreg Project Codex4SME. A total of four award winners will receive a grant of approximately 100,000 Euros each, in the form of laboratory services by the Integrated Biobank of Luxembourg. Read More

Exclusive access to biobank service

Posted on

Four companies from Germany, France and the Netherlands have been presented with the Biomarker Validation Award as part of Codex4SMEs. The European project aims to establish a transnational network to accelerate the development of companion diagnostics along the entire value chain of small and medium-sized enterprises. The award is endowed with approximately EUR 100,000, which is handed over in the form of laboratory services. The chosen companies can now have their respective biomarkers validated by the Integrated Biobank of Luxembourg – in other words, have them tested to assess their reliability with regard to their relevant indication. Read More

Presentation of the webinar with Tom Miller

Posted on

Finding capital to fund your (companion) diagnostics SME: The Venture Capital perspective. On 28 May, a webinar with Tom Miller in the frame of the Interreg NWE project 'Codex4SMEs' took place. Tom Miller is founder of Greybird Ventures and is dedicated to invest in companies that can help to eliminate "trial and error" medicine with high-specifity diagnostics and generate value for patients, providers, developers of therapies, and those who pay for healthcare. Read More

Save the date: Webinar with Tom Miller (Greybird Ventures), May 28th

Posted on

Finding capital to fund your (companion) diagnostics SME: The Venture Capital perspective. The Interreg NWE project 'Codex4SMEs' proudly announces a webinar with Tom Miller, founder of Greybird Ventures, who is dedicated to invest in companies that can help to eliminate "trial and error" medicine with high-specifity diagnostics and generate value for patients, providers, developers of therapies, and those who pay for healthcare. Read More

Idris Oncology one of first companies to receive free human tissue through Codex4SME’s

Posted on

The Leiden based biotechnology firm Idris Oncology is one of the three SME’s in Europe to receive human tissue through the Codex4SME’s consortium, in order to help them progress their diagnostic product towards clinical application. Interreg project Codex4SME's supports entrepreneurs in Life Sciences & Health sector in obtaining human tissue from biobanks. The application process for tissue can be very lingering and complicated. Read More